Tiger's Take
We are moving away from the era of "one size fits all" orthopedics. We’ve mastered the metal and plastic; now we have to master the immunology.
ExplantLab is the first company to give surgeons a practical, scalable way to screen for biological compatibility. When they hit the US market, I expect to see rapid adoption from high-volume centers of excellence and ASCs that want to drive their revision rates down to zero.
If you’re a surgeon, an investor, or an implant rep, keep your eyes on ExplantLab. The "Mystery Pain" era is coming to a close, and the era of Immunological Orthopedi...
